T A Splinter|T C Kok - JoVE Visualize

Showing results (1-10 of 103) with videos related to

Pageof 11

Sort By:

Acta Oncologica (Stockholm, Sweden)|January 1, 1988

Etoposide and cisplatin in advanced esophageal cancer. A preliminary reportT C Kok, T A Splinter, J Verweij

Seminars in Oncology|April 1, 1992

A phase I study of daily oral teniposide for 20 daysE F Smit, T A Splinter, T C Kok

Journal of Cancer Research and Clinical Oncology|January 1, 1989

Adjuvant chemotherapy after resection of adenocarcinoma of the periampullary region and the head of the pancreas. A non-randomized pilot studyT A Splinter, H Obertop, T C Kok, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 1996

5-fluorouracil and folinic acid in advanced adenocarcinoma of the esophagus or esophago-gastric junction area. Rotterdam Esophageal Tumor Study GroupT C Kok, A van der Gaast, T A Splinter

Seminars in Oncology|December 1, 1992

What is the optimal dose and duration of treatment with etoposide? I. Maximum tolerated duration of daily treatment with 50, 75, and 100 mg of oral etoposideT A Splinter, A van der Gaast, T C Kok

European Urology|January 1, 1991

Growing teratoma syndrome successfully treated with lymphoblastoid interferonA van der Gaast, T C Kok, T A Splinter

Seminars in Oncology|December 1, 1992

What is the optimal dose and duration of treatment with etoposide? II. Comparative pharmacokinetic study of three schedules: 1 x 100 mg, 2 x 50 mg, and 4 x 25 mg of oral etoposide daily for 21 daysA van der Gaast, M Vlastuin, T C Kok, et al.

Seminars in Oncology|April 1, 1992

Absolute bioavailability and pharmacokinetics of oral teniposideT A Splinter, J J Holthuis, T C Kok, et al.

Cancer|October 15, 1991

Sarcoid-like lymphadenopathy mimicking metastatic testicular cancerT C Kok, J G Haasjes, T A Splinter, et al.

European Journal of Cancer (Oxford, England : 1990)|January 1, 1991

Ifosfamide in advanced adenocarcinoma of the oesophagus or oesophageal-gastric junction area. Rotterdam Esophageal Tumor Study GroupT C Kok, A van der Gaast, T A Splinter, et al.

Pageof 11

Showing results (1-10 of 103) with videos related to

Sort By:

Pageof 11

Acta Oncologica (Stockholm, Sweden)|January 1, 1988

Etoposide and cisplatin in advanced esophageal cancer. A preliminary reportT C Kok, T A Splinter, J Verweij

Seminars in Oncology|April 1, 1992

A phase I study of daily oral teniposide for 20 daysE F Smit, T A Splinter, T C Kok

Journal of Cancer Research and Clinical Oncology|January 1, 1989

Adjuvant chemotherapy after resection of adenocarcinoma of the periampullary region and the head of the pancreas. A non-randomized pilot studyT A Splinter, H Obertop, T C Kok, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 1996

5-fluorouracil and folinic acid in advanced adenocarcinoma of the esophagus or esophago-gastric junction area. Rotterdam Esophageal Tumor Study GroupT C Kok, A van der Gaast, T A Splinter

Seminars in Oncology|December 1, 1992

What is the optimal dose and duration of treatment with etoposide? I. Maximum tolerated duration of daily treatment with 50, 75, and 100 mg of oral etoposideT A Splinter, A van der Gaast, T C Kok

European Urology|January 1, 1991

Growing teratoma syndrome successfully treated with lymphoblastoid interferonA van der Gaast, T C Kok, T A Splinter

Seminars in Oncology|December 1, 1992

What is the optimal dose and duration of treatment with etoposide? II. Comparative pharmacokinetic study of three schedules: 1 x 100 mg, 2 x 50 mg, and 4 x 25 mg of oral etoposide daily for 21 daysA van der Gaast, M Vlastuin, T C Kok, et al.

Seminars in Oncology|April 1, 1992

Absolute bioavailability and pharmacokinetics of oral teniposideT A Splinter, J J Holthuis, T C Kok, et al.

Cancer|October 15, 1991

Sarcoid-like lymphadenopathy mimicking metastatic testicular cancerT C Kok, J G Haasjes, T A Splinter, et al.

European Journal of Cancer (Oxford, England : 1990)|January 1, 1991

Ifosfamide in advanced adenocarcinoma of the oesophagus or oesophageal-gastric junction area. Rotterdam Esophageal Tumor Study GroupT C Kok, A van der Gaast, T A Splinter, et al.

Pageof 11